Quest Diagnostics INC Form 4 insider transactions

Mark E Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc, sold 1,600 shares of common stock on July 28, 2026 for $235.18 per share.

Karthik Kuppusamy, SVP, Clinical Solutions of Quest Diagnostics Inc, reported a transaction in 37 shares of common stock on July 22, 2026.

Robert B Carter, a Director of Quest Diagnostics Inc, reported a transaction in 11 shares of common stock on July 22, 2026.

Vicky B Gregg, a Director of Quest Diagnostics Inc, received 72 shares of common stock on July 22, 2026.

Patrick Plewman, SVP for Diagnostic Services of Quest Diagnostics Inc, reported a transaction in 46 shares of common stock on July 22, 2026.

Timothy L Main, a Director of Quest Diagnostics Inc, reported a transaction in 21 shares of common stock on July 22, 2026.

Sam Samad, Executive Vice President & CFO of Quest Diagnostics Inc, received 102 shares of common stock on July 22, 2026.

Wright Lassiter Iii, a Director of Quest Diagnostics Inc, reported a transaction in 6 shares of common stock on July 22, 2026.

Mark E Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc, reported a transaction in 34 shares of common stock on July 22, 2026.

Quest Diagnostics Director Timothy C. Wentworth reports acquisition of phantom stock units under a deferred compensation plan.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, executed a series of stock transactions, including exercising options and selling shares, under a Rule 10b5-1 plan.

Quest Diagnostics CEO James E. Davis sold 10,000 shares of common stock on June 1, 2026, under a pre-arranged 10b5-1 trading plan.

Quest Diagnostics Director Robert B. Carter acquired 1,142 shares of common stock through an award of restricted stock units.

Quest Diagnostics Director Vicky B. Gregg acquired 1,142 shares of common stock through an award of restricted stock units.

Quest Diagnostics Director Luis Diaz acquired 1,142 shares of common stock.

Quest Diagnostics Director Timothy L. Main acquired 1,142 shares of common stock.

Quest Diagnostics Director Timothy C. Wentworth acquired 1,142 shares of common stock through an award of restricted stock units.

Tracey Doi, a Director at Quest Diagnostics, acquired 1,142 shares of common stock on May 20, 2026, as part of a restricted stock unit award.

Director Timothy M. Ring acquired 1,142 shares of Quest Diagnostics common stock through an award of restricted stock units.

Quest Diagnostics Director Wright Lassiter III acquired 1,142 shares of common stock through an award of restricted stock units.

Quest Diagnostics Director Denise M. Morrison acquired 1,142 shares of common stock through an award of restricted stock units.

Quest Diagnostics Director Gary M. Pfeiffer acquired 1,142 shares of common stock through an award of restricted stock units.

Quest Diagnostics CFO Sam Samad acquired 108 shares of common stock through a dividend reinvestment plan.

SVP Patrick Plewman acquired 49 shares of Quest Diagnostics common stock through a dividend reinvestment plan.

Quest Diagnostics Director Vicky B. Gregg acquired 68 shares of common stock through a dividend reinvestment plan.

Quest Diagnostics Director Robert B. Carter acquired 7 shares of common stock through a dividend reinvestment plan.

Director Wright L. Lassiter III acquired 6 shares of Quest Diagnostics common stock through a dividend reinvestment plan.

SVP of Clinical Solutions Karthik Kuppusamy acquired 39 shares of Quest Diagnostics common stock via a dividend reinvestment plan.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 37 shares through a dividend reinvestment plan.

Timothy C. Wentworth, a Director at Quest Diagnostics Inc., reported the acquisition of 198 phantom stock units on April 1, 2026, as part of his director compensation.